Clinical Trial

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-02-12; most recent amendment 2026-01-13.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06830850
Lead Sponsor Atridia Pty Ltd.
Conditions Metastatic Castration Resistant Prostate Cancer
Enrollment 25 participants
Start Date 2025-06-15
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-15